About UsWho We Are

Dr Paul Harper, Chairman

Dr Paul Harper, Chairman

Dr Paul Harper has over 30 years' experience in the life sciences industry covering both drug development and medical devices. He is Chairman of Physiomics plc, Sareum plc, Angel Biotechnology Holdings plc and Director of Reneuron Holdings plc, all AIM quoted companies.  In addition, he is chairman of FDAS Ltd, and Monica Healthcare Ltd. Paul has served as Chief Executive of Cambridge Antibody Technology Limited, and founded Provensis Limited. He has also served as Corporate Development Director of Unipath Limited, then the medical diagnostics business of Unilever PLC, and as Director of Research and Development for Johnson & Johnson Limited. Formerly head of Antimicrobial Chemotherapy for Glaxo PLC, Paul has a PhD in Molecular Virology and is the author of over 50 publications.

   
Dr Mark Chadwick, Chief Executive Officer

Dr Mark Chadwick, Chief Executive Officer

Mark joined Physiomics from EnviroGene in December 2010.  Previously he was VP of Business Development at Excelsyn, a chemistry services provider, where he grew turnover to £14m and EBITDA to £1m. Excelsyn was subsequently acquired by AMRI for $19m. Prior to that he led the Development Services Business Unit at Excelsyn, growing the customer base from scratch to over 80 in 3 years.  Before joining Excelsyn, Mark spent 10 years in Cambridge from startup company (Cambridge Genetics Limited) through two mergers to become Director of Commercial Operations at BioFocus, a £15m turnover, profitable drug discovery services provider. BioFocus was subsequently acquired by the Belgian biotechnology company Galapagos for $40m.

Mark is a former Fellow of Corpus Christi College Cambridge. He holds an MBA with distinction in Entrepreneurship from Imperial College London, a PhD in Molecular Biology from The University of Newcastle and a 1st Class (Hons) degree in Genetics from the University of Nottingham.

   
Dr Christophe Chassagnole, Chief Operating Officer

Dr Christophe Chassagnole, Chief Operating Officer

Dr Christophe Chassagnole has been involved in systems biology and bio-computing projects since the mid-nineties, with experience in both academic and industrial environments. His Doctorate was achieved at the Victor Segalen-Bordeaux II University, and then he held a post doctorate position with IBVT at Stuttgart University. Before Joining Physiomics Dr Chassagnole worked in France as a senior researcher for CRITT Bio-Industries (Toulouse) for 3 years. He joined Physiomics in May 2004 as project leader to develop the model portfolio of the company. He was appointed Chief Operating Officer of Physiomics in May 2007.

   
Mr Roger Jones, Financial Controller and Company Secretary

Mr Roger Jones, Financial Controller and Company Secretary

Mr. Jones has for 30 years been a Fellow of the Association of Chartered Certified Accountants and has held a number of senior financial positions and key roles in biotechnology and pharmaceutical companies including Cambridge Antibody Technology, Onyvax, Archimedes Pharma, Angel Biotechnology and Provensis.

   
Dr Eric Fernandez, Project Leader

Dr Eric Fernandez, Project Leader

Eric Fernandez gained his doctorate in molecular and cellular genetics from Paris 6 University with the highest distinction award, and his MSc in computing science from Imperial College, London. Eric started his scientific career as a "wet lab" scientist, working on prion diseases at the Molecular Genetics Centre at Gif-sur-Yvette, France, the Atomic Energy Commissariat (CEA) at Fontenay-aux-Roses, France and later at the University of Kent at Canterbury. For his work on prion diseases he received the “Nine Choukroun” award from the CRNS in 2001. Showing interest in more theoretical fields of biology, he trained in bioinformatics at the Pasteur Institute, Paris and in computing science at Imperial College, London. He had his first experience in systems biology, at the European Bioinformatics Institute in Cambridge, UK, modelling signal integration in the neuron. He later joined Physiomics in November 2006 as Senior Scientist and was promoted to Project Leader in 2010.

   
Dr Frances Brightman, Senior Simulation Scientist

Dr Frances Brightman, Senior Simulation Scientist

Frances Brightman is a computational biology specialist, with 10 years’ post-doctoral experience in both commercial and academic environments. In 2001 she was awarded a PhD from Oxford Brookes University, where she worked with Professor David Fell on the modelling and simulation of cell signalling processes. For the next seven years Frances was employed by Cyprotex, a CRO specialising in preclinical ADME toxicology, to formulate, implement and validate physiologically-based pharmacokinetic (PBPK) models; she subsequently returned to David Fell’s group at Oxford Brookes University for three years to investigate dynamic modelling and quantitative analysis of mammalian mitochondrial metabolism. Frances joined Physiomics in September 2010 as a senior simulation scientist.

   
HM - Square - Highres

Dr Hitesh Mistry, Senior Simulation Scientist

Dr Hitesh Mistry, holds a PhD in Applied Mathematics from The University of Manchester and is now a modelling and simulation specialist within the pharmaceutical industry.  He has worked in projects from target identification (systems biology) through to clinical development (population PKPD) in a variety of therapeutic areas with particular focus on Oncology.  His work in early clinical oncology at AstraZeneca, building a translational disease model for Prostate Cancer, culminated in being awarded an AstraZeneca Oncology Innovation Award in 2012.  Furthermore, he was also involved in developing and deploying the first systems biology/pharmacology project routinely used within AstraZeneca in the cardiac toxicity area. Hitesh joined Physiomics in January 2013, as a senior simulation scientist, to lead the Virtual Tumour clinical development.

   
Professor David Fell, Chief Scientific Officer

Professor David Fell, Co-Founder and Scientific Advisory Board member

David Fell is Professor of Biochemistry and he is Assistant Dean of the School of Life Sciences at Oxford Brookes University and is recognised as an expert in systems biology and metabolic modelling. Professor Fell runs a research team at Oxford Brookes University where current projects include the analysis of the structure of metabolic networks, the computer simulation of signal transduction and elementary modes for the analysis of metabolism and metabolic engineering. He is the author or co-author more than 100 scientific publications attracting over 5000 citations and has written one of the standard textbooks, ‘‘Understanding the Control of Metabolism’’ in the area of metabolic control analysis. David has held positions in, or chaired, a number of editorial boards, policy committees and international strategy panels in metabolic engineering and systems biology. Professor Fell has been involved with the Company since 2001.

   
Dr David Orrell, Principal Consultant, Modelling & Simulation

Dr David Orrell, Principal Consultant, Modelling & Simulation and Scientific Advisory Board member

David Orrell is an applied mathematician, with a PhD from Oxford University on the prediction of nonlinear systems. He has worked in diverse areas including weather forecasting, economics, and systems biology, and at Physiomics is working on model development. He has written over 20 research papers, and is the author of several books including The Future of Everything: The Science of Prediction.

For more information please see www.systemsforecasting.com.

   
Mrs Charmaine Fraser, Administration Manager

Mrs Charmaine Fraser, Administration Manager

Charmaine Fraser joined Physiomics in 2008, bringing with her over 10 years of Administrative and Managerial experience. In Charmaine’s previous employment she was an Office Manager for an Automotive Rental company that had dealings with the MOD. With her vast skill base and her structured and methodical approach to her role, she is able to coordinate the running of the administrative side of the company, ensuring that it runs smoothly and in a timely manner.